KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Current Assets (2018 - 2025)

Historic Current Assets for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $281.4 million.

  • Adaptive Biotechnologies' Current Assets fell 872.72% to $281.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.4 million, marking a year-over-year decrease of 872.72%. This contributed to the annual value of $283.8 million for FY2024, which is 3082.39% down from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Current Assets of $281.4 million as of Q3 2025, which was down 872.72% from $261.9 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Current Assets high stood at $765.0 million for Q1 2021, and its period low was $256.5 million during Q1 2025.
  • For the 5-year period, Adaptive Biotechnologies' Current Assets averaged around $431.8 million, with its median value being $419.1 million (2022).
  • In the last 5 years, Adaptive Biotechnologies' Current Assets crashed by 4676.89% in 2021 and then skyrocketed by 3957.76% in 2022.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Current Assets stood at $402.7 million in 2021, then surged by 39.58% to $562.1 million in 2022, then fell by 27.03% to $410.2 million in 2023, then plummeted by 30.82% to $283.8 million in 2024, then dropped by 0.82% to $281.4 million in 2025.
  • Its last three reported values are $281.4 million in Q3 2025, $261.9 million for Q2 2025, and $256.5 million during Q1 2025.